Budimex S.A. (BDX)
Warsaw Stock Exchange · Poland · prices in PLN · close of 22 Oct 2026
Key indicators
| Last close | PLN 704.00 |
|---|---|
| 52-week range | 531.00 – 814.00 |
| Return, 1 month / 3 months | −1.9% / −6.1% |
| Return, 1 year / 3 years | +35.7% / +74.2% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 33.3% |
| Worst drawdown (1 year) | -22.4% |
| Average daily value traded | 23.17M PLN |
| Dividend yield | 4.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Budimex is a Polish construction and engineering group based in Warsaw. It builds roads, motorways, bridges and railway infrastructure, and it also acts as a general contractor for residential, commercial and industrial buildings. Its customers are mainly public bodies such as road and rail authorities, along with private developers and companies. The group also provides construction-related services and operates in neighbouring markets. Budimex belongs to the Spanish infrastructure group Ferrovial.
On this site Budimex S.A. appears as a stock on the Warsaw Stock Exchange (Poland), code BDX, with prices in Polish zloty (PLN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Budimex S.A. (BDX) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 704.00 on 22 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 97 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 35.7% and over the last three months it fell 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.9% | ||
| From 52-week high | -12.8% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.1% | ||
| 6-month return | 1.9% | ||
| 12-month return, skipping the last month | 38.3% | ||
| Stability (higher is calmer) | 72 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 33.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.4% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 23.17M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | 60 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.7% |
|---|---|
| 1 month | −1.9% |
| 3 months | −6.1% |
| 6 months | +1.9% |
| 1 year | +35.7% |
| 3 years | +74.2% |
| 5 years | +252.9% |
Signals
| 50-day / 200-day average | 701.92 / 691.07 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 18.58 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2026 | PLN 32.4200 |
| 4 Jun 2025 | PLN 25.4300 |
| 28 May 2024 | PLN 35.6900 |
| 24 May 2023 | PLN 17.9900 |
| 30 May 2022 | PLN 23.4700 |
| 8 Oct 2021 | PLN 14.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.